

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-139. (Canceled).

140. (New) A pharmaceutical formulation comprising
a glycodendrimer of 3.5 generations or less or
a combination of glycodendrimers of 3.5 generations or less
wherein said glycodendrimers comprise an anion carboxylic terminated dendrimer core
and a monosaccharide linked such that a carboxy group on said core forms an amide bond with a
nitrogen on the monosaccharide, and

said monosaccharide is selected from the group consisting of:

glucosamine or an N-acetyl derivative thereof, and

glucosamine-6-sulphate or an N-acetyl derivative thereof;

wherein the amount of glucosamine monosaccharide linked to the dendrimer core
expressed as a percentage of converted carboxylic acid groups is in the range 1.5% to 10.1% and
wherein the amount of glucosamine sulphate monosaccharide linked to the dendrimer core
expressed as a percentage of converted carboxylic acid groups is in a range of 1.5% to 15%.

141. (New) A pharmaceutical formulation according to claim 140, wherein the amount
of glucosamine moiety linked to the dendrimer core expressed as a percentage of converted
carboxylic acid groups is about 7%.

142. (New) A pharmaceutical formulation according to claim 140, wherein the sulphate
moiety linked to the dendrimer core expressed as a percentage of converted carboxylic acid
groups is about 7%

143. (New) A pharmaceutical formulation according to claim 140, wherein dendrimer core is PAMAN.

144. (New) A pharmaceutical formulation comprising a 3.5 generation glycodendrimer of an anion carboxylic terminated PAMAN core and monosaccharide linked such that a carboxy group on the core forms an amide bond with a nitrogen on the monosaccharide, said glycodendrimer selected from the group consisting of:

PAMAN-glucosamine or an N-acetyl derivative thereof,

PAMAN-glucosamine-6-sulphate or an N-acetyl derivative thereof; and

a combination thereof

wherein the amount of glucosamine moiety linked to the dendrimer core expressed as a percentage of converted carboxylic acid groups is in the range 1.5% to 10.1% and the amount of sulphate present is less than 15%.

145. (New) A pharmaceutical formulation according to claim 140, wherein the glycodendrimer is present at a concentration in the range 100-200 μ g/mL.